Emergent BioSolutions Files 8-K on Dec 12, 2025
Ticker: EBS · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financial-statements
TL;DR
Emergent BioSolutions filed an 8-K on 12/12/25 for Reg FD and exhibits.
AI Summary
Emergent BioSolutions Inc. filed an 8-K on December 12, 2025, reporting on events that occurred on the same date. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD Disclosure. No specific financial figures or material events beyond the filing itself are detailed in the provided text.
Why It Matters
This filing indicates that Emergent BioSolutions Inc. is making a regulatory disclosure and submitting financial exhibits, which is standard practice for public companies to keep investors informed.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification and does not contain information about specific material events, financial performance, or significant risks.
Key Players & Entities
- Emergent BioSolutions Inc. (company) — Registrant
- December 12, 2025 (date) — Date of Report
- 300 Professional Drive, Gaithersburg, Maryland 20879 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and to provide Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is December 12, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 300 Professional Drive, Gaithersburg, Maryland 20879.
What is the Commission File Number for Emergent BioSolutions Inc.?
The Commission File Number for Emergent BioSolutions Inc. is 001-33137.
What is the IRS Employer Identification Number (EIN) for the registrant?
The IRS Employer Identification Number (EIN) for the registrant is 14-1902018.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-12-12 08:29:53
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share EBS New York Stock
Filing Documents
- ebs-20251212.htm (8-K) — 27KB
- a12122025raxi.htm (EX-99.1) — 17KB
- image2a.jpg (GRAPHIC) — 7KB
- 0001367644-25-000207.txt ( ) — 202KB
- ebs-20251212.xsd (EX-101.SCH) — 2KB
- ebs-20251212_def.xml (EX-101.DEF) — 15KB
- ebs-20251212_lab.xml (EX-101.LAB) — 26KB
- ebs-20251212_pre.xml (EX-101.PRE) — 16KB
- ebs-20251212_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 12, 2025, Emergent BioSolutions Inc. (the "Company") issued a press release regarding the Company's receipt of U.S. Food and Drug Administration approval for drug product manufacturing of raxibacumab at the Company's Winnipeg manufacturing site, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in any such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Emergent BioSolutions Inc. on December 12, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: December 12, 2025 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer